Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 1905180Search this ID in NIH RePORTER
- ScienceDex PI coverage
- FY2024 through FY2025Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2025
Linked Award Amount
$4.7M
Full award amounts, FY2025
Award Records
5
Records listing this PI
Award-Linked Rank
#1,578
By linked amount among FY2025 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2025 award records by amount
NIH award records listing Jeff T Hutchins as a PI. Multi-PI records show the full award amount for context.
- 5R44AI181347-02R44IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection$1Maward amount
- 5R44AI177199-02R44SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections$1Maward amount
- 1R44AI191921-01A1R44Development of IN-003PI as passive immunization against human metapneumovirus infection$1Maward amount
- 1R44AI188967-01A1R44IND-enabling development for IN-005, an inhaled muco-trapping mAb therapy against Influenza A$1Maward amount
- 5SB1AI179368-03SB1GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus$608.8Kaward amount
Award organization
Organizations that administered FY2025 awards listing Jeff T Hutchins as a PI.
FY2025 award administered by Inhalon Biopharma, Inc. (NC).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardInhalon Biopharma, Inc.
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024$2M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #1579
- 2024Entered Top 25% NationallyRanked #1579
- 2024Entered Top 10% NationallyRanked #1579
- 2025$5M Cumulative Funding